TNGX
Tango Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$23.18
+0.04%Nov 4, 2026, 13:30 UTC
Tango Therapeutics, Inc. and Erasca, Inc. announced that their Phase 1/2 study of vopimetostat combined with ERAS-0015 is open for enrollment in patients with specified MTAP-deleted cancers.
Source:Oct 26, 2026, 16:46 UTC
Tango Therapeutics, Inc. shares fell 16.4%.
Source:Oct 23, 2026, 15:36 UTC
Tango Therapeutics, Inc. shared Phase 1/2 trial data for investigational vopimetostat in advanced pancreatic and lung cancers.
Source:Oct 23, 2026, 10:30 UTC
Tango Therapeutics, Inc. reported Phase 1/2 study results for vopimetostat plus daraxonrasib in second- and third-line pancreatic cancer, including an 82% objective response rate and a 9-month progression-free survival rate of 88%; median progression-free survival had not been reached.
Aug 11, 2026, 00:00 UTC
Tango Therapeutics reported Q2 2026 financial results with zero revenue, a net loss of $55.3 million, and diluted EPS of -$0.37, while highlighting a 92% objective response rate for vopimetostat plus daraxonrasib and a 90% six-month progression-free survival rate.
Source:Aug 6, 2026, 22:24 UTC
Tango Therapeutics announced that Executive Chairman Dr. Barbara Weber will step down in connection with other pursuits.
Source:Jun 10, 2026, 02:49 UTC
Tango Therapeutics priced an upsized public offering of common stock and pre-funded warrants to raise approximately $600 million.
Source:Jun 9, 2026, 17:46 UTC
Tango Therapeutics released early pancreatic cancer study results for vopimetostat combinations, showing strong response rates and supporting late-stage plans.